Putting a Price on Human Eggs Makes No Sense
By Debora Spar,
Fortune
| 11. 21. 2015
Untitled Document
There’s something funny about the U.S. market for eggs. No, not the kind that spring from chickens and go into making pancakes, but those that come from humans and go into making babies. These eggs – tiny bundles of reproductive DNA – are produced by young women at the peak of their fertility. They are sold in the United States for anywhere between $5,000 and $50,000. And they exist in an Alice in Wonderland world of explicit denial, where prices are capped far below their open-market value and even the most expensive transactions are classified, universally, as “donations.”
The market for human eggs is a fairly recent development, prodded into existence by the explosive growth of in vitro fertilization (IVF) technologies in the 1990s and 2000s. Once it became possible — and then eventually commonplace — to create babies conceived outside the womb, it quickly also became possible to build those babies from other parties’ genes. By the mid-1990s, couples who suffered from male infertility, along with a growing numbers of lesbian couples and single women, were...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...